CUE BIOPHARMA INC (CUE) Stock Income Statement
NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.99M | 9.29M | 5.49M | 1.25M | 14.94M | |||
| Operating Expenses | 49.21M | 50.88M | 57.48M | 54.75M | 58.65M | |||
| Research and Development | 34.64M | 35.93M | 40.28M | 37.76M | 40.19M | |||
| Selling, General, and Administrative Expenses | 14.57M | 14.57M | 16.66M | 16.15M | 17.29M | |||
| Operating Income | -41.22M | -41.59M | -51.99M | -53.50M | -43.71M | |||
| Interest Income/Expense | 546.00K | 826.00K | 1.42M | 210.00K | 20.00K | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | N/A | 93.00K | -157.00K | 280.00K | N/A | |||
| Income Before Taxes | -40.58M | -40.67M | -50.73M | -53.01M | -43.67M | |||
| Income Tax | N/A | N/A | N/A | 0.00 | 500.00K | |||
| Net Income | -40.58M | -40.67M | -50.73M | -53.01M | -44.16M | |||
| EBITDA | -40.82M | -41.20M | -51.44M | -52.58M | -42.45M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.66 | -0.72 | -1.11 | -1.49 | -1.41 | |||
| Non GAAP EPS | -0.67 | -0.75 | -1.11 | -1.50 | -1.40 | |||
| Statistics | ||||||||
| Profit Margin | -507.87% | -437.97% | -924.10% | -4240.80% | -295.58% | |||
| Operating Profit Margin | -515.87% | -447.86% | -947.03% | -4280.00% | -292.57% | |||
All data in USD